STOCK TITAN

Ionis to hold fourth quarter and full year 2025 financial results webcast

(Moderate)
(Neutral)
Tags
earnings date

Key Terms

webcast technical
A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Webcast scheduled for Wednesday, February 25 at 11:30 a.m. Eastern Time

CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 25 at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2025 financial results and highlight progress on key programs.

The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.

About Ionis Pharmaceuticals, Inc.

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.

Ionis Investor Contact:
D. Wade Walke, Ph.D. – IR@ionis.com 760-603-2331

Ionis Media Contact:
Hayley Soffer – media@ionis.com – 760-603-4679

Source: Ionis Pharmaceuticals, Inc.